Hill A - Search Results

1

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.

Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A. Antinori A, et al. Among authors: hill a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19525. doi: 10.7448/IAS.17.4.19525. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394034 Free PMC article.

2

Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

Hill A, Miralles D, Vangeneugden T, Lefebvre E. Hill A, et al. AIDS. 2007 Jul 31;21(12):1651-3. doi: 10.1097/QAD.0b013e3282703593. AIDS. 2007. PMID: 17630565

3

Causes and consequences of incomplete HIV RNA suppression in clinical trials.

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A. Pozniak A, et al. Among authors: hill a. HIV Clin Trials. 2009 Sep-Oct;10(5):289-98. doi: 10.1310/hct1005-289. HIV Clin Trials. 2009. PMID: 19906623 Review.

4

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. Arribas JR, et al. Among authors: hill a. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944. AIDS. 2010. PMID: 20010070 Clinical Trial.

5

Friedewald equation underestimates low-denisty lipoprotein elevations for patients with high triglyceride levels in the ARTEMIS and TITAN trials.

Nelson M, DeMasi R, Moecklinghoff C, Hill AM. Nelson M, et al. J Acquir Immune Defic Syndr. 2010 Jan;53(1):151-3. doi: 10.1097/QAI.0b013e3181c0b05c. J Acquir Immune Defic Syndr. 2010. PMID: 20035166 No abstract available.

6

Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.

Winston A, Fätkenheuer G, Arribas J, Hill A, van Delft Y, Moecklinghoff C. Winston A, et al. Among authors: hill a. HIV Clin Trials. 2010 May-Jun;11(3):163-9. doi: 10.1310/hct1103-163. HIV Clin Trials. 2010. PMID: 20736152 Clinical Trial.

7

Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.

Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Fox J, et al. Among authors: hill a. AIDS Res Hum Retroviruses. 2011 Jan;27(1):29-34. doi: 10.1089/aid.2010.0081. Epub 2010 Sep 21. AIDS Res Hum Retroviruses. 2011. PMID: 20854196 Clinical Trial.

8

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.

Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, van Delft Y, Vingerhoets J, Stark T, Marks S. Nelson M, et al. Among authors: hill a. AIDS. 2011 Jan 28;25(3):335-40. doi: 10.1097/QAD.0b013e3283416873. AIDS. 2011. PMID: 21150563

9

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E. Hill AM, et al. Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182345 Clinical Trial.

10

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Pulido F, et al. Among authors: hill a. Antivir Ther. 2011;16(1):59-65. doi: 10.3851/IMP1710. Antivir Ther. 2011. PMID: 21311109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,574 results

Search Page

Filters